On GLP-1 medications where you might already struggle with reduced fluid intake , this is especially important to remember
The queries for the articles about mechanism of GLP-1RAs in liver disease and the clinical experiments: ((GLP-1RAs[Title/Abstract]) OR (GLP-1R agonists[Title/Abstract]) OR (GLP-1 receptor agonists[Title/Abstract]) OR (GLP-1 receptor[Title/Abstract])) AND ((liver[Title/Abstract]) OR (hepatic[Title/Abstract]) OR (HCC[Title/Abstract]) OR (fibrosis[Title/Abstract]) OR (cirrhosis[Title/Abstract]) OR (NAFLD[Title/Abstract]) OR (MASLD[Title/Abstract])) AND ((inflammation[Title/Abstract]) OR (immun*[Title/Abstract]) OR (T cell[Title/Abstract]) OR (B cell[Title/Abstract]) OR (NK cell[Title/Abstract]) OR (macrophage[Title/Abstract]))
DM, MAS, EAS, TA, and MH wrote and revised the manuscript
However, navigating insurance coverage for these medications can feel overwhelming
Ozempic often used off-label) Tirzepatide (Zepbound / Mounjaro) a dual GLP-1/GIP agonist that tends to produce even greater weight loss Liraglutide (Saxenda) Originally developed for Type 2 diabetes, these medications received Health Canada approval for chronic weight management in adults with a BMI 30, or BMI 27 with at least one weight-related condition (such as hypertension, dyslipidemia, or obstructive sleep apnea)